SARS-CoV-2 in multiple myeloma: initial observation and management

Elisabet E. Manasanch; Victor Mulanovich; Joanna Grace Manzano; Maria Susan Gaeta; Melody Becnel; Gregory P. Kaufman; Hans C. Lee; Behrang Amini; Sheeba K. Thomas; Swaminathan P. Iyer; Donna M. Weber; Zuzana Berkova; Christopher R. Flowers; Robert Z. Orlowski; Krina K. Patel

doi:10.1080/10428194.2020.1780588

SARS-CoV-2 in multiple myeloma: initial observation and management

Elisabet E. Manasanch, Victor Mulanovich, Joanna Grace Manzano, Maria Susan Gaeta, Melody Becnel, Gregory P. Kaufman, Hans C. Lee, Behrang Amini, Sheeba K. Thomas, Swaminathan P. Iyer, Donna M. Weber, Zuzana Berkova, Christopher R. Flowers, Robert Z. Orlowski, Krina K. Patel

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	2763-2766
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2020.1780588
State	Published - Nov 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1080/10428194.2020.1780588

Cite this

Manasanch, E. E., Mulanovich, V., Manzano, J. G., Gaeta, M. S., Becnel, M., Kaufman, G. P., Lee, H. C., Amini, B., Thomas, S. K., Iyer, S. P., Weber, D. M., Berkova, Z., Flowers, C. R., Orlowski, R. Z., & Patel, K. K. (2020). SARS-CoV-2 in multiple myeloma: initial observation and management. Leukemia and Lymphoma, 61(11), 2763-2766. https://doi.org/10.1080/10428194.2020.1780588

@article{aebb9a1f55b446d58091bd9a08fcc87f,

title = "SARS-CoV-2 in multiple myeloma: initial observation and management",

author = "Manasanch, {Elisabet E.} and Victor Mulanovich and Manzano, {Joanna Grace} and Gaeta, {Maria Susan} and Melody Becnel and Kaufman, {Gregory P.} and Lee, {Hans C.} and Behrang Amini and Thomas, {Sheeba K.} and Iyer, {Swaminathan P.} and Weber, {Donna M.} and Zuzana Berkova and Flowers, {Christopher R.} and Orlowski, {Robert Z.} and Patel, {Krina K.}",

note = "Funding Information: C. R. Flowers declares being a consultant in the past 3 years for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum. Research Funding in the past 12 months: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation. Funding Information: K. Patel has received consulting fees from Celgene, BMS, Janssen, Takeda, Pfizer, Precision Biosciences, Oncopeptides, Nektar andd research support from Celgene, BMS, Janssen, Poseida, Cellectis, Takeda, Abbvie, Precision Biosciences, and Nektar. Funding Information: This work was also supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society (SCOR-12206-17), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, The Chapman Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia & Lymphoma Society (SCOR-12206-17), the Brock Family Myeloma Research Fund, and the Jean Clarke High-Risk Myeloma Research Fund. We would like to thank participating patients and their families. Funding Information: R. Orlowski declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and is a Founder of Asylia Therapeutics, Inc., with an equity interest. ",

year = "2020",

month = nov,

doi = "10.1080/10428194.2020.1780588",

language = "English (US)",

volume = "61",

pages = "2763--2766",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - SARS-CoV-2 in multiple myeloma

T2 - initial observation and management

AU - Manasanch, Elisabet E.

AU - Mulanovich, Victor

AU - Manzano, Joanna Grace

AU - Gaeta, Maria Susan

AU - Becnel, Melody

AU - Kaufman, Gregory P.

AU - Lee, Hans C.

AU - Amini, Behrang

AU - Thomas, Sheeba K.

AU - Iyer, Swaminathan P.

AU - Weber, Donna M.

AU - Berkova, Zuzana

AU - Flowers, Christopher R.

AU - Orlowski, Robert Z.

AU - Patel, Krina K.

N1 - Funding Information: C. R. Flowers declares being a consultant in the past 3 years for Abbvie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, MEI Pharmaceuticals, Pharmacyclics/Janssen, Spectrum. Research Funding in the past 12 months: Abbvie, Acerta, Celgene, Gilead, Genentech/Roche, Janssen Pharmaceutical, Millennium/Takeda, Pharmacyclics, TG Therapeutics, Burroughs Wellcome Fund, CPRIT, Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation. Funding Information: K. Patel has received consulting fees from Celgene, BMS, Janssen, Takeda, Pfizer, Precision Biosciences, Oncopeptides, Nektar andd research support from Celgene, BMS, Janssen, Poseida, Cellectis, Takeda, Abbvie, Precision Biosciences, and Nektar. Funding Information: This work was also supported in part by The MD Anderson Cancer Center Support Grant (P30 CA016672), the Leukemia and Lymphoma Society (SCOR-12206-17), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Multiple Myeloma Research Foundation, The Chapman Perelman Foundation, and the University of Texas MD Anderson Moon Shot Program. RZO, the Florence Maude Thomas Cancer Research Professor, would like to acknowledge support from the National Cancer Institute (R01s CA184464 and 194264, and U10 CA032102), the Leukemia & Lymphoma Society (SCOR-12206-17), the Brock Family Myeloma Research Fund, and the Jean Clarke High-Risk Myeloma Research Fund. We would like to thank participating patients and their families. Funding Information: R. Orlowski declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and is a Founder of Asylia Therapeutics, Inc., with an equity interest.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85087005703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087005703&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1780588

DO - 10.1080/10428194.2020.1780588

M3 - Letter

C2 - 33167721

AN - SCOPUS:85087005703

SN - 1042-8194

VL - 61

SP - 2763

EP - 2766

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

SARS-CoV-2 in multiple myeloma: initial observation and management

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this